RVNC
Revance Therapeutics, Inc.
NASDAQ: RVNC · HEALTHCARE · BIOTECHNOLOGY
$3.65
+0.00% today
Updated 2026-04-30
Market cap
$381.02M
P/E ratio
—
P/S ratio
1.48x
EPS (TTM)
$-3.34
Dividend yield
—
52W range
$0 – $0
Volume
4.1M
Revance Therapeutics, Inc. (RVNC) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-71.80%
Operating margin
-53.90%
ROE
-2,097.00%
ROA
-24.40%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2011 | $557000.00 | $-44.86M | 99.10% | -4,979.89% | -8,054.40% |
| 2012 | $717000.00 | $-58.26M | 100.00% | -6,023.15% | -8,125.38% |
| 2013 | $617000.00 | $-52.45M | 100.00% | -6,195.30% | -8,500.49% |
| 2014 | $383000.00 | $-62.92M | 100.00% | -13,590.08% | -16,427.42% |
| 2015 | $300000.00 | $-73.48M | -565.00% | -24,105.67% | -24,492.00% |
| 2016 | $300000.00 | $-89.27M | 100.00% | -29,405.00% | -29,756.67% |
| 2017 | $262000.00 | $-120.59M | 100.00% | -45,963.36% | -46,025.57% |
| 2018 | $3.73M | $-142.57M | -2,380.56% | -3,824.99% | -3,823.22% |
| 2019 | $413000.00 | $-156.22M | -24,805.81% | -39,820.58% | -37,824.94% |
| 2020 | $15.32M | $-282.09M | 68.88% | -1,782.46% | -1,840.71% |
| 2021 | $77.80M | $-286.82M | 69.91% | -353.06% | -368.68% |
| 2022 | $132.56M | $-356.42M | 61.03% | -205.31% | -268.87% |
| 2023 | $234.04M | $-323.99M | 34.98% | -135.35% | -138.43% |